Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 12/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.37 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11936683 | 0.83 | CCR9 (0.71) | CCR9MAPTALDH1A1LMNAGAA | |
| SCHEMBL11937066 | 0.82 | CCR9 (0.67) | CCR9MAPTALDH1A1LMNAKCNK2 | |
| SCHEMBL343780 | 0.79 | CCR9 (0.78) | CCR9 | |
| SCHEMBL14034474 | 0.77 | CCR9 (0.53) | CCR9SMN1; SMN2 | |
| SCHEMBL11938257 | 0.77 | CCR9 (0.53) | CCR9SMN1; SMN2 | |
| SCHEMBL11938245 | 0.76 | CCR9 (0.65) | CCR9SMN1; SMN2KCNK2KCNK10 | |
| SCHEMBL13664748 | 0.76 | CCR9 (0.41) | CCR9MAPTLMNAGAA | |
| SCHEMBL11937175 | 0.75 | CCR9 (0.55) | CCR9LMNAHTTSMN1; SMN2 | |
| SCHEMBL11938267 | 0.74 | CCR9 (0.55) | CCR9LMNAHTTSMN1; SMN2 | |
| SCHEMBL11936670 | 0.72 | CCR9 (0.48) | CCR9LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20080293717-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885MAPT 4194/4885ALDH1A1 1655/4885 |
| US-20080293717-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | CCR9 1/4885MAPT 4194/4885ALDH1A1 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.